Sponsored Links
| Ironwood And Forest Announce Positive Linaclotide Results From Phase 3 Trial In Patients With Irritable Bowel Syndrome With Constipation |
 |
 |
 |
| Medical News - Irritable-Bowel Syndrome | |||
|
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from the firs of two Phase 3 clinical trials assessing the efficacy and safety of the investigational drug, linaclotide, in patients with irritable bowel syndrome with constipation (IBS-C)... Read more: Irritable-Bowel Syndrome News From Medical News Today
|